Opening Recap
Market Pulse: US stocks closed with a mixed tone yesterday — big tech shrugged off a slow start, financials lagged, and health care edged higher after a stream of earnings and FDA approvals.
Key Movers: UnitedHealth topped estimates and boosted guidance in a late Q3 report (UnitedHealth Earnings Beat Wall Street Estimates. Slashdot.org), Accord BioPharma won FDA approval for FILKRI™ (Accord BioPharma Launches FILKRI. PRNewswire), and crypto traders are still reeling from multi-year highs in ETH longs.
Macro & Politics: Robert F. Kennedy Jr.’s push for looser peptide access (Some peptide users report lasting symptoms. Yahoo Entertainment) is stirring a medical-freedom fight, with emerging reports of lingering side effects outpacing the policy headlines.
What’s Next: All eyes turn to tomorrow’s inflation prints and consumer-sentiment figures, while Fed speakers and ongoing Q3 reports will set the next market tone.
Market Commentary
Everyone’s missing the mounting custody risk in crypto that could trigger another sell-off. While ETH longs spiked to multi-year highs—setting up speculative mania—Ledger just yanked its wallets in Southeast Asia after one device was rigged to leak recovery phrases (Here’s what happened in crypto today. Cointelegraph). That kind of damnable hack can snowball into a trust crisis just when traders are overleveraged.
Meanwhile, health care is getting a free-market wingback as UnitedHealth smashed Q3 forecasts and raised guidance (UnitedHealth Earnings Beat Wall Street Estimates. Slashdot.org), yet you’ve got Robert F. Kennedy Jr. championing peptide freedom while some users report neurological setbacks (Some peptide users report lasting symptoms. Yahoo Entertainment). That clash between corporate efficiency and unregulated hype underscores how policy posturing can upend capital allocation.
If you’re looking for a playbook, own companies with real pricing power and robust risk controls—think the health insurers nailing margins—and steer clear of overleveraged crypto plays or experimental drug mania until the liability landscape clears. Don’t get blindsided by a catchy political promise; focus on cash flow, audits, and supply stability.
📈 Breaking Financial News
UnitedHealth Earnings Beat Wall Street Estimates. The Turnaround Continues. – Barron's
UnitedHealth Earnings Beat Wall Street Estimates. The Turnaround Continues.Barron's UnitedHealth Group tops estimates, hikes profit outlook as insurer manages high medical costsCNBC UnitedHealth posts $4B profit in comeback from financial spiralStar Tribune U…
UnitedHealth Group raises profit forecast on third-quarter earnings beat – Yahoo Finance
UnitedHealth Group raises profit forecast on third-quarter earnings beatYahoo Finance UnitedHealth Group tops estimates, hikes profit outlook as insurer manages high medical costsCNBC UnitedHealth raises profit forecast again as turnaround efforts gather pace…
UnitedHealth Group raises profit forecast on third-quarter earnings beat
By Amina Niasse
NEW YORK, Oct 13 (Reuters) – UnitedHealth Group (UNH) on Tuesday raised its 2026 profit forecast as the company tightened spending on medical costs in its health insurance business and improved margins in its Optum clinical care and health tec…
Here’s what happened in crypto today
Ledger just pulled the plug on its hardware wallet sales in six Southeast Asian countries and Hong Kong after finding at least one device rigged with an unauthorized implant that leaks your recovery phrase to thieves. Rival Trezor, smelling trouble, is slashing its own reseller network as a precaution. And Europe’s electronics giant MediaMarktSaturn yanked all Ledger stock offline and off shelves until this shit-show is over.
Chip tool giant ASML nudges up outlook as AI-driven demand outruns supply
Oct 14 : ASML said on Wednesday that AI-driven demand for its chip-printing tools is so strong that it will not be able to fully meet customer demand in 2027 or 2028 and that it is looking at ways to expand capacity as it raised its full-year sales outlook.Th…
🔍 Market Analysis & Insights
JPMorgan records rare earnings miss, Goldman Sachs delivers blowout revenue in mixed quarter
JPMorgan – the largest US bank by assets and the largest in the world by market cap – reported earnings per share of $5.57, missing estimates of $5.90. It recorded revenue of $50.91 billion, below expectations of $51.22 billion.
Wells Fargo beats profit estimates, NII and revenue fall short
Wells Fargo beats profit estimates, NII and revenue fall shorttheglobeandmail.com
Some peptide users report lasting symptoms as RFK Jr. pushes for wider access
After the third day of squirting an experimental drug up his nose, Dylan Meetze felt horrible.”It was like I was underwater, like it took the most to do anything,” he said.Subscribe to The Post Most newsletter for the most important and interesting stories fr…
Rebecca Solnit's (Mis)Adventures in the Manosphere
Rebecca Solnit
Rebecca Solnit explores an America where the right has turned hatred of women into an ever-expanding, multi-platform Internet grift.
The post Rebecca Solnit's (Mis)Adventures in the Manosphere appeared first on The Nation.
People Say These Peptides Hurt Them. Their Stories Are Muffled in MAHA’s Push for Medical Freedom.
People who have taken experimental peptides, such as BPC-157, complain of migraines, eye pain, fatigue, and more. Learning whether these popular but unproven drugs are to blame may become harder if Robert F. Kennedy Jr. fulfills a promise to make them more ac…
💰 Investment Opportunities
Psychedelic medicine is approaching a turning point. The U.S. needs the right infrastructure to be ready
Today’s psychedelics bear little resemblance to 1970s counterparts. These medicines undergo rigorous clinical trials and licensed manufacturing processes.
Accord BioPharma Launches FILKRI™ (filgrastim-laha); Now Offers Both Long- and Short-Acting G-CSF Options
FILKRI is available with a permanent Q-code, standardizing the billing and reimbursement process across all sites of care. RALEIGH, N.C., Oct. 12, 2026 /PRNewswire/ — Accord BioPharma, Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on t…
When Only AI Can See the Cancer
Scientists are developing new AI tools that have the power to spot lethal cancers, including of the pancreas, on imaging while they are still nascent enough to cure. The long-term impact may one day transform cancer-survival rates.
Sebela Pharmaceuticals to Present Positive Phase 3 Tegoprazan Data in Non-Erosive Reflux Disease (NERD) at the American College of Gastroenterology (ACG) 2026 Meeting
Key Highlights: Tegoprazan is the first and only P-CAB reported to demonstrate clinical improvement in both hallmark symptoms of NERD, heartburn and regurgitation, in a prospective U.S. phase 3 clinical trial. Detailed analysis from the randomized, double-bli…
Efferon wants to eradicate the devastating toll of pediatric sepsis | TechCrunch
Efferon wants to eradicate the devastating toll of pediatric sepsis | TechCrunchtechcrunch.com